{"id":90794,"date":"2023-04-24T13:17:39","date_gmt":"2023-04-24T11:17:39","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?post_type=ecosystem&#038;p=90794"},"modified":"2023-04-24T13:17:41","modified_gmt":"2023-04-24T11:17:41","slug":"rnatics-gmbh","status":"publish","type":"ecosystem","link":"https:\/\/cms.munich-startup.net\/en\/startups\/rnatics-gmbh\/","title":{"rendered":"RNATICS GmbH"},"content":{"rendered":"<div class=\"entry-content\"><p>RNATICS develops drugs based on short nucleic acid molecules, so-called oligonucleotides, that target disease-causing RNAs in tissue-resident macrophages.<\/p>\n<p>This novel delivery mechanism enables access to organs that were previously inaccessible to nucleic acid therapies, thus opening up great therapeutic potential in many diseases.<\/p>\n<p>We plan to start the first clinical trial (Phase I) of our lead candidate, RCS-21, for the treatment of fibrosing lung diseases following viral infections (e.g., COVID-19) in spring 2024.<\/p>\n<\/div>","protected":false},"featured_media":90795,"comment_status":"closed","ping_status":"closed","template":"","tags":[],"ecosystem_type":[2],"ecosystem_tag":[2708,2707,2713],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>RNATICS GmbH - Munich Startup<\/title>\n<meta name=\"description\" content=\"Das M\u00fcnchner BioTech Startup RNATICS entwickelt Medikamente basierend auf kurzen Nukleins\u00e4ure-Molek\u00fclen, sogenannten Oligonukleotiden.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/startups\/rnatics-gmbh\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RNATICS GmbH - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Das M\u00fcnchner BioTech Startup RNATICS entwickelt Medikamente basierend auf kurzen Nukleins\u00e4ure-Molek\u00fclen, sogenannten Oligonukleotiden.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/startups\/rnatics-gmbh\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-24T11:17:41+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/\",\"url\":\"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/\",\"name\":\"RNATICS GmbH - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/04\/RNATICS-GmbH-1.jpeg\",\"datePublished\":\"2023-04-24T11:17:39+00:00\",\"dateModified\":\"2023-04-24T11:17:41+00:00\",\"description\":\"Das M\u00fcnchner BioTech Startup RNATICS entwickelt Medikamente basierend auf kurzen Nukleins\u00e4ure-Molek\u00fclen, sogenannten Oligonukleotiden.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/04\/RNATICS-GmbH-1.jpeg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/04\/RNATICS-GmbH-1.jpeg\",\"width\":2000,\"height\":2000,\"caption\":\"RNATICS GmbH\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RNATICS GmbH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2023\/04\/RNATICS-GmbH-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"2000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RNATICS GmbH - Munich Startup","description":"The Munich-based biotech startup RNATICS develops drugs based on short nucleic acid molecules, so-called oligonucleotides.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/startups\/rnatics-gmbh\/","og_locale":"en_US","og_type":"article","og_title":"RNATICS GmbH - Munich Startup","og_description":"Das M\u00fcnchner BioTech Startup RNATICS entwickelt Medikamente basierend auf kurzen Nukleins\u00e4ure-Molek\u00fclen, sogenannten Oligonukleotiden.","og_url":"https:\/\/cms.munich-startup.net\/en\/startups\/rnatics-gmbh\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_modified_time":"2023-04-24T11:17:41+00:00","twitter_card":"summary_large_image","twitter_site":"@munich_startup","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/","url":"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/","name":"RNATICS GmbH - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/04\/RNATICS-GmbH-1.jpeg","datePublished":"2023-04-24T11:17:39+00:00","dateModified":"2023-04-24T11:17:41+00:00","description":"The Munich-based biotech startup RNATICS develops drugs based on short nucleic acid molecules, so-called oligonucleotides.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/04\/RNATICS-GmbH-1.jpeg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/04\/RNATICS-GmbH-1.jpeg","width":2000,"height":2000,"caption":"RNATICS GmbH"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/startups\/rnatics-gmbh\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"RNATICS GmbH"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]},"og_image":[{"width":2000,"height":2000,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/04\/RNATICS-GmbH-1.jpeg","type":"image\/jpeg"}]},"_location_name":"","_location_street":"Am Klopferspitz 19a","_location_zip":"82152","_location_city":"Martinsried","_ecosystem_type":"startup","_foundingyear":"2021","_showyear":"1","_show_financing":"","_inactive":"","_founders":"3","_employees":"4","_businessmodel":"B2B","_stage":"Startup-Stage","_financing":"","_investors":"","_investor_funding_rounds":"","_investor_details":"","_financing_history":"[{\"ecosystem_funding_round\":\"Seed\",\"ecosystem_funding_year\":\"2021\",\"ecosystem_funding_amount\":\"1.000.001 - 2.000.000 Euro\"}]","_apple_appstore":"","_google_play":"","_user_email":"info@rnatics.com","_user_password":"$2y$10$m6kWoUjGkHz95hlCkEF\/JuJV9QBL\/ZJbIoQ69FWLHsBzn\/O\/sRfpy","_description_en":"RNATICS develops therapeutics based on RNA-molecules, so called oligonucleotides, to target disease-causing RNAs in tissue resident macrophages, specific cells of the immunce system. This novel way of delivery enables access to organs previously not accessible to nucleic acid therapy offering tremendous therapeutic opportunities for multiple diseases. We aim to start first-in-human clinical trials with our lead candidate, RCS-21, treating fibrotic lung injuries after viral infections (such as COVID-19) in early 2024.","_founders_description":"","_founders_image":"","_logo_image":"","_contact":{"tel":"","hp":"https:\/\/www.rnatics.com\/","mail":"info@rnatics.com","facebook":"","twitter":"","instagram":"","linkedin":""},"_thumbnail_id":"90795","_edit_lock":"1772614859:25","_edit_last":"25","_location_lat":"48.1076814","_location_long":"11.4593875","_wp_old_slug":"rnatics-gmbh-2","wbounce_status":"default","_yoast_wpseo_primary_ecosystem_type":"2","_yoast_wpseo_primary_ecosystem_tag":"2707","_hide_on_map":"","_yoast_wpseo_content_score":"30","dealroom_id":"4212682","_dealroom_id":"field_5ea15c1318719","dealroom_json":"{\"id\":4212682,\"name\":\"RNATICS GmbH\",\"url\":\"https:\/\/app.dealroom.co\/companies\/rnatics\",\"total_funding\":0,\"employees_chart\":[{\"date\":\"2022-06-29\",\"value\":1},{\"date\":\"2022-07-29\",\"value\":1},{\"date\":\"2022-08-27\",\"value\":1},{\"date\":\"2022-09-26\",\"value\":1},{\"date\":\"2022-10-25\",\"value\":1},{\"date\":\"2022-11-24\",\"value\":1},{\"date\":\"2022-12-24\",\"value\":1},{\"date\":\"2023-01-24\",\"value\":1}],\"employees_latest\":1,\"employee_12_months_growth_unique\":null,\"employee_12_months_growth_percentile\":null,\"app_12_months_growth_percentile\":null,\"app_12_months_growth_unique\":null,\"app_12_months_growth_relative\":null,\"fundings\":{\"items\":[],\"total\":0}}","_dealroom_json":"field_5ea15c251871a","dealroom_analytics_json":"{\"twitter_followers_chart\":[],\"facebook_likes_chart\":[]}","_dealroom_analytics_json":"field_5ea8354f2b0eb","_yoast_wpseo_focuskw":"RNATICS","_yoast_wpseo_metadesc":"Das M\u00fcnchner BioTech Startup RNATICS entwickelt Medikamente basierend auf kurzen Nukleins\u00e4ure-Molek\u00fclen, sogenannten Oligonukleotiden.","_yoast_wpseo_linkdex":"43","_yoast_wpseo_estimated-reading-time-minutes":"1","_wp_old_date":"","_wp_desired_post_slug":"","_year":"","_yoast_wpseo_wordproof_timestamp":"","_yoast_wpseo_focuskw_text_input":"","_original_post_id":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/ecosystem\/90794"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/ecosystem"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/ecosystem"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=90794"}],"version-history":[{"count":1,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/ecosystem\/90794\/revisions"}],"predecessor-version":[{"id":90798,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/ecosystem\/90794\/revisions\/90798"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/90795"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=90794"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=90794"},{"taxonomy":"ecosystem_type","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/ecosystem_type?post=90794"},{"taxonomy":"ecosystem_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/ecosystem_tag?post=90794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}